ZYME NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Zymeworks Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 21.94 USD
-4.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -9.4% below the Trend Line and sits at 57.2% of its 52-week range. The latest completed week returned -4.0%, after a -16.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is volatility with 60/100 conviction, while the latest news-sentiment score is 59/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 26 out of 100
Latest Close 21.94 USD 31 Jul 2026
1W Return -4.0% latest completed week
4W Return -16.6% short-term follow-through
12W Return -8.2% quarterly tape
Trend Breadth 82.7% 43 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.0% Latest completed week; four-week move -16.6%. Indicator stack 45/22 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 60/100 conviction; expected move 22.2%. News sentiment 59/100 56 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -9.4% below the Trend Line and sits at 57.2% of its 52-week range. The latest completed week returned -4.0%, after a -16.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3812-week average 0.52

12-week confirmation

Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.38Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers

No recent accumulation markers. 3 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -16.6% over four weeks, -8.2% over 12 weeks, and 74.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.0%
4W-16.6%
12W-8.2%
26W-2.6%
52W74.5%
Active trend streak0 weeks
Active weeks in one year43
Trend breadth82.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.24Latest activity-pressure read.
Pressure change-72.1%Four-week change in activity pressure.
Leadership-9.21Latest relative-leadership reading.
RS change-223.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength18/100Blend of value, momentum, and quality. Underlying universe rank 83; rank 1 is best.
Value14/100Relative valuation strength. Underlying universe rank 87; rank 1 is best.
Quality19/100Profitability and accounting quality. Underlying universe rank 82; rank 1 is best.
Momentum91/100Medium-term price momentum. Underlying universe rank 10; rank 1 is best.
Growth16/100Revenue and earnings growth. Underlying universe rank 85; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
20.7x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-5.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
94.4%
Gross profit retained from each unit of revenue.
Operating margin
-128.8%
Operating profit retained from revenue.
Free-cash-flow margin
-89.8%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-13.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
2.2%
Net share repurchases relative to market value.
Shareholder yield
2.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ZYME shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 14.43, expected move of 22.2%, and Sharemaestro trend signal inactive.

Conviction60/100
Expected move22.2%
Put/call volume14.43
Pressure-82
Speculation9
Volatility89
Trend agreement57
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment59/100

Weighted news tone is neutral across 56 relevant articles.

27 positive · 26 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move22.2%Nearest-chain priced movement where available.
52-week drawdown-26.3%Distance below the 52-week high.
13-week volatility5.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+8.9%Week of 3 Jul.
Worst week-10.2%Week of 8 May.
Latest week-4.0%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains10
Flat weeks0
Modest losses3
Sharp losses8
Recent vol5.3%13-week weekly-return volatility.
Base vol7.2%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew5.5% / -4.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape31/100

Trend, activity pressure, participation, and risk combine to a 31/100 tape read.

 Indicator analysis38/100

Latest 12-week confirmation: trend 6/12, activity pressure 2/12, relative leadership 8/12.

Activity pressure 0.38; 3 reversal markers Factors32/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 22; Small Cap Core rank 83 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options54/100

ZYME shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 14.43, expected move of 22.2%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 22.2% Sentiment59/100

Weighted news tone is neutral across 56 relevant articles.

Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Analysts Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202621.94 USD-4.0%24.23 USD14.74 USD-1.24-9.211.7MOff
24 Jul 202622.86 USD-5.5%24.38 USD14.65 USD-0.88-4.412.0MOff
17 Jul 202624.19 USD-6.5%24.52 USD14.55 USD-0.710.081.9MOn
10 Jul 202625.88 USD-1.6%24.62 USD14.45 USD-0.683.153.4MOn
3 Jul 202626.31 USD8.9%24.60 USD14.33 USD-0.727.453.3MOff
26 Jun 202624.15 USD4.4%24.62 USD14.21 USD-0.660.233.0MOff
19 Jun 202623.14 USD1.1%24.70 USD14.12 USD-0.53-7.692.5MOff
12 Jun 202622.88 USD-4.8%24.73 USD14.02 USD-0.26-5.893.9MOff
5 Jun 202624.04 USD-4.3%24.59 USD13.92 USD-0.131.604.5MOn
29 May 202625.13 USD-1.9%24.33 USD13.82 USD-0.122.022.5MOn
22 May 202625.61 USD7.0%24.13 USD13.72 USD0.097.723.0MOn
15 May 202623.93 USD0.2%23.87 USD13.61 USD0.282.653.8MOn
8 May 202623.89 USD-10.2%23.68 USD13.52 USD0.522.823.4MOn
1 May 202626.61 USD-5.3%23.49 USD13.43 USD0.5621.573.0MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.